BR112013009164A2 - capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada. - Google Patents

capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada.

Info

Publication number
BR112013009164A2
BR112013009164A2 BR112013009164A BR112013009164A BR112013009164A2 BR 112013009164 A2 BR112013009164 A2 BR 112013009164A2 BR 112013009164 A BR112013009164 A BR 112013009164A BR 112013009164 A BR112013009164 A BR 112013009164A BR 112013009164 A2 BR112013009164 A2 BR 112013009164A2
Authority
BR
Brazil
Prior art keywords
rotavirus
norovirus
protein
vaccine
combined vaccine
Prior art date
Application number
BR112013009164A
Other languages
English (en)
Inventor
Jokela Eeva
Nurminen Kirsi
Huhti Leena
Lappalainen Suvi
Vesikari Timo
Blazevic Vesna
Original Assignee
Vesikari Timo
Blazevic Vesna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vesikari Timo, Blazevic Vesna filed Critical Vesikari Timo
Publication of BR112013009164A2 publication Critical patent/BR112013009164A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Abstract

capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada. a presente invenção refere-se a um notovírus combinadas e vacina contra o rotavírus para a prevenção da infecção por rotavírus e norovírus e / orviral induzida diarreia e vómitos homem dis-easesin. mais especificamente, a invenção compreende um método ofpreparing composições de combinação de vacina compreendendo antígenos de norovírus e rotavírus, em especial misturas de vlps de norovírus e proteína vp6 de rotavírus recombinante ou de camada dupla vp2/vp6 vlps. além disso, a invenção refere-se a métodos para a indução de uma resposta imune.
BR112013009164A 2010-10-14 2011-10-12 capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada. BR112013009164A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39308110P 2010-10-14 2010-10-14
FI20106067A FI122520B (fi) 2010-10-15 2010-10-15 Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
PCT/FI2011/050880 WO2012049366A1 (en) 2010-10-14 2011-10-12 Norovirus capsid and rotavirus vp6 protein for use as combined vaccine

Publications (1)

Publication Number Publication Date
BR112013009164A2 true BR112013009164A2 (pt) 2019-09-24

Family

ID=43064225

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009164A BR112013009164A2 (pt) 2010-10-14 2011-10-12 capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada.

Country Status (14)

Country Link
US (1) US8895015B2 (pt)
EP (1) EP2627353B1 (pt)
JP (1) JP5902181B2 (pt)
KR (1) KR101847472B1 (pt)
CN (1) CN103260645B (pt)
AU (1) AU2011315405B2 (pt)
BR (1) BR112013009164A2 (pt)
CA (1) CA2814175C (pt)
FI (1) FI122520B (pt)
MX (1) MX352478B (pt)
RU (1) RU2013121815A (pt)
SG (1) SG189398A1 (pt)
TW (1) TWI479022B (pt)
WO (1) WO2012049366A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5284290B2 (ja) 2007-03-14 2013-09-11 リゴサイト ファーマスーティカルズ，インコーポレイテッド ウイルス様粒子の精製
JP5817836B2 (ja) 2011-10-24 2015-11-18 トヨタ自動車株式会社 組換え酵母を用いたエタノールの製造方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN103667199B (zh) * 2012-09-20 2019-01-22 厦门大学 体外制备轮状病毒双层类病毒颗粒的方法
ES2762631T3 (es) 2013-03-14 2020-05-25 Harvard College Composiciones a base de nanopartículas
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
JP2018078806A (ja) * 2016-11-14 2018-05-24 東ソー株式会社 ノロウイルスｒｎａの検出方法
CA3053522A1 (en) * 2017-03-28 2018-10-04 Children's Hospital Medical Center Norovirus s particle based vaccines and methods of making and using same
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
JP6879111B2 (ja) 2017-08-02 2021-06-02 トヨタ自動車株式会社 組換え酵母及びこれを用いたエタノールの製造方法
KR102038364B1 (ko) 2018-03-15 2019-10-30 전남대학교 산학협력단 소 로타바이러스 감염증 예방용 약독화 혼합생백신 조성물
US20230285534A1 (en) 2020-01-08 2023-09-14 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
CN111265660B (zh) * 2020-01-19 2022-11-15 青岛明勤生物科技有限公司 一种通用型疫苗免疫增强剂
CN114316009B (zh) * 2020-09-29 2023-04-25 上海交通大学 一种能够结合多种病毒的蛋白及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298244A (en) * 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
PT100090A (pt) 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
JP2000139473A (ja) * 1998-11-16 2000-05-23 Hokkaido Green Bio Kenkyusho:Kk ロタウイルス遺伝子を導入した遺伝子組換え植物、この遺伝子組換え植物に由来するロタウイルスのタンパク質及びこのロタウイルスのタンパク質に対する抗体
US20030166139A1 (en) 2001-07-20 2003-09-04 Choi Anthony H. Rotavirus VP6 subunit
US8277819B2 (en) * 2005-06-16 2012-10-02 Children's Hospital Medical Center Norovirus particle for use as an antiviral or vaccine
WO2007009081A2 (en) * 2005-07-07 2007-01-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A hexavalent bovine rotavirus reassortant composition designed for use in developing countries
JP5215865B2 (ja) * 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
AU2008302276B2 (en) * 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
JP5284290B2 (ja) * 2007-03-14 2013-09-11 リゴサイト ファーマスーティカルズ，インコーポレイテッド ウイルス様粒子の精製
US20110123546A1 (en) * 2008-04-18 2011-05-26 Frenken Leo Gerardus J Compositions Comprising Antibodies or Antibody Fragments
WO2010006326A2 (en) * 2008-07-11 2010-01-14 Tufts University Methods and compositions for spore-based vaccines
WO2010144602A2 (en) 2009-06-09 2010-12-16 Children's Hospital Medical Center Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use

Also Published As

Publication number Publication date
CA2814175A1 (en) 2012-04-19
FI20106067A0 (fi) 2010-10-15
EP2627353A1 (en) 2013-08-21
AU2011315405B2 (en) 2016-09-22
TW201217530A (en) 2012-05-01
MX2013004159A (es) 2013-11-04
EP2627353A4 (en) 2014-06-18
KR20140030100A (ko) 2014-03-11
US8895015B2 (en) 2014-11-25
CA2814175C (en) 2019-11-05
EP2627353B1 (en) 2017-11-29
CN103260645A (zh) 2013-08-21
MX352478B (es) 2017-11-27
US20120093884A1 (en) 2012-04-19
SG189398A1 (en) 2013-05-31
CN103260645B (zh) 2016-03-16
AU2011315405A1 (en) 2013-05-23
KR101847472B1 (ko) 2018-04-11
FI122520B (fi) 2012-03-15
RU2013121815A (ru) 2014-11-20
JP2013540773A (ja) 2013-11-07
TWI479022B (zh) 2015-04-01
WO2012049366A1 (en) 2012-04-19
JP5902181B2 (ja) 2016-04-13

Similar Documents

Publication Publication Date Title
BR112013009164A2 (pt) capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada.
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201790109A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
EA201290884A1 (ru) Устойчивые к спирту кишечнорастворимые фармацевтические композиции
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
EA201391240A1 (ru) Слитые белки и комбинированные вакцины, содержащие белок е и пилин а haemophilus influenza
EA201691348A1 (ru) Однофлаконные вакцинные составы
WO2011103453A3 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2013054199A3 (en) Cmv antigens and uses thereof
CL2012003299A1 (es) Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
NZ729519A (en) Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
EA201591451A1 (ru) Модуляторы flap
DK2709656T3 (da) Proteinmatrix-vaccinesammensætninger omfattende polykationer
EP2949341A4 (en) RECOMBINANT ANTIGENS OF SWINE CIRCOVIRUS-2 (PCV-2) FOR VACCINATE FORMULATIONS, DIAGNOSIS KIT AND USE THEREOF
PL2575872T3 (pl) Zatężanie antygenów szczepionkowych grypy bez liofilizacji
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
BR112013013016A2 (pt) modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14
WO2014140166A3 (en) Vaccine
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.